$BPMX“Following the closing of the merger, the combined company will also evaluate BioPharmX's Phase 3 ready proprietary topical minocycline gel programs for a strategic partnership, co-development or other non-dilutive value creation strategy. This product has previously been studied by BioPharmX in the treatment of inflammatory lesions of acne vulgaris and papulopustular rosacea"
$ACI Albertsons initiated with a Buy at Citi Citi analyst Paul Lejuez initiated coverage of Albertsons with a Buy rating and $22 price target. The company is "winning in this uncertain environment" and is well positioned to capitalize on eat at home trends, Lejuez tells investors in a research note. Following its initial public offering on June 26, the stock is down 3%, presenting an attractive entry point for a pure play food retailer, says the analyst.
ECOR Analyst Ratings CONSENSUS Strong Buy Based on 2 analysts offering recommendations for ecor in the last 3 months.
Analyst Firms Making Recommendations H C WAINWRIGHT NOBLE FINANCIAL Analyst $3.5 Based on analysts offering 12 month price targets for ECOR in the last 3 months. The average price target is $3.5 with a high estimate of $4 and a low estimate of $3. Sign in to your SmartPortfolio to see more analyst recommendations.